AstraZeneca wraps up Brilinta study enrollment early; Former Pharmacia chief dies at 74; Sanofi sued over arthritis marketing;

@FiercePharma: Best-read special report over the weekend: Top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> AstraZeneca ($AZN) completed enrollment in a study of its bloodthinner Brilinta in patients with peripheral artery disease. Report

> A former Pharmacia Corp. chairman and CEO, John Zabriskie, died in Colorado last week; he was 74. Report

> Canadian drugmaker Elorac sued Sanofi's ($SNY) Canadian unit for $20 million in a breach-of-contract lawsuit that accuses the French drugmaker of failing to market an arthritis cream as agreed. Report

> India's Natco Pharma won tentative FDA approval to sell a generic version of Roche's ($RHHBY) influenza pill Tamiflu. Report

Medical Device News

@FierceMedDev: Teleflex's vascular system gains pivotal FDA clearance--the product comes from a previous M&A deal. More | Follow @FierceMedDev

@MarkHFierce: Mela Sciences' 2013 financials show how tough a relaunch of its skin cancer Dx tool will be. Story | Follow @MarkHFierce

@MichaelGFierce: SynapDx, Broad Institute align to make autism Dx with next-gen sequencing. Item | Follow @MichaelGFierce

@EmilyWFierce: Evidence of world's oldest case of metastatic cancer found in a skeleton in the Sudan. Article | Follow @EmilyWFierce

> OrbiMed backs an Israeli startup developing a futuristic, handheld diagnostic device. News

> St. Jude Medical will test its leadless pacemaker in a massive EU post-marketing trial. Story

> FDA puts the brakes on Avedro with complete response letter on KXL System. More

Biotech News

@FierceBiotech: AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project. More | Follow @FierceBiotech

@JohnCFierce: Upbeat review of failed PhII DMD trial earns Prosensa a big boost to shares. News | Follow @JohnCFierce

@DamianFierce: A quarter of European doctors can't define biosimilars. Story via Bloomberg. | Follow @DamianFierce

@EmilyMFierce: Snails and quails in today's issue of FierceBiotech Research. | Follow @EmilyMFierce

> Meet RestorGenex, a biotech mosaic from Celgene founder Barer. News

> Eager biotechs eye $133M in IPOs as a frenzied quarter closes. Article

Biotech Research News

> Capturing leukemic stem cells may help propel new drug discovery. More

> Study: Chickens, quails are likely to blame for spread of H7N9. Piece

> Drug derived from snail venom could treat chronic pain with fewer side effects. Article

> Compound stops formation of toxic peptides in mice with Alzheimer's. More

> NIH cuts, sequestration hampering cancer research. Story

> Stem cell therapy improves tendon healing in preclinical study. Item

Pharma Manufacturing News

> Japan's Eisai intends to nearly triple production to 2 billion tablets at its plant in Vizag, India. Report

> The FDA has added two Chinese drug manufacturing facilities to its list of banned plants. Alerts

> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. Report

> Ranbaxy Laboratories insists the drugs it sells in India are safe and effective. Story

> Optel Visions is expanding its inspection systems offerings. Release

And Finally... More science grads are earning specialized MBAs to win bioinformatics jobs. Report

Suggested Articles

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.

As the election nears, and amid the drumbeat of COVID-19 news, the Trump administration unveiled a new drug pricing initiative.